Introduction: Intra-arterial chemotherapy (IAC) is useful for eye preservation in advanced retinoblastoma (Rb). Intra-vitreal chemotherapy (IvitC) is the latest treatment for vitreous seeds. Methods: The present study is a retrospective assessment of 100 eyes, treated with primary or secondary IAC alone or with IvitC. We evaluated demographic and clinical variables, eye salvage, associated adverse events, and patient survival. Data were analyzed using descriptive statistics. Kaplan-Meier survival curves and Cox hazard ratios were utilized to assess the effect of demographic and clinical variables over eye salvage. Results: Bilateral Rb was observed in 61% of patients, and 57% of eyes received secondary treatment. Forty eyes needed intra-arterial plus IvitC and 62 presented advanced disease (group D and E). Three- and 5-year ocular survival probabilities were 75 and 68%. We found a higher risk in group D and E eyes and those requiring 2 or more routes for ophthalmic artery catheterization. Patients coming from other countries also showed increased risk. Using primary or secondary treatment, or IvitC, did not affect this risk. Overall rates of survival and eye salvages were 98.8 and 73%, and we had a 100% catheterization success and none ophthalmic arterial occlusions. Conclusions: In an upper middle-income country such as Colombia, a specialized institution counting with therapeutic alternatives and a multidisciplinary team can reach rates of patient survival and eye salvage similar to those of high-income countries.

1.
Pekacka
A
.
The role of intraarterial chemotherapy in the management of retinoblastoma
.
J Ophthalmol
.
2020
;
2020
:
3638410
. .
2.
Abramson
DH
,
Dunkel
IJ
,
Brodie
SE
,
Kim
JW
,
Gobin
YP
.
A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results
.
Ophthalmology
.
2008
;
115
(
8
):
1398
e1
. .
3.
Shields
CL
,
Fulco
EM
,
Arias
JD
,
Alarcon
C
,
Pellegrini
M
,
Rishi
P
, et al.
Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy
.
Eye
.
2013
;
27
(
2
):
253
64
. .
4.
Yamane
T
,
Kaneko
A
,
Mohri
M
.
The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma
.
Int J Clin Oncol
.
2004
;
9
(
2
):
69
73
. .
5.
Zage
PE
,
Reitman
AJ
,
Seshadri
R
,
Weinstein
JL
,
Mets
MB
,
Zeid
JL
, et al.
Outcomes of a two-drug chemotherapy regimen for intraocular retinoblastoma
.
Pediatr Blood Cancer
.
2008
;
50
(
3
):
567
72
.
6.
Turaka
K
,
Shields
CL
,
Meadows
AT
,
Leahey
A
.
Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma
.
Pediatr Blood Cancer
.
2012 Jul 15
;
59
(
1
):
121
5
. .
7.
Abramson
DH
,
Daniels
AB
,
Marr
BP
,
Francis
JH
,
Brodie
SE
,
Dunkel
IJ
, et al.
Intra-arterial chemotherapy (ophthalmic artery chemosurgery) for group D retinoblastoma
.
PLoS One
.
2016
;
11
(
1
):
e0146582
. .
8.
Dalvin
LA
,
Kumari
M
,
Essuman
VA
,
Shohelly Shipa
S
,
Ancona-Lezama
D
,
Lucio-Alvarez
JA
, et al.
Primary intra-arterial chemotherapy for retinoblastoma in the intravitreal chemotherapy era: five years of experience
.
Ocul Oncol Pathol
.
2019
;
5
(
2
):
139
46
. .
9.
Shields
CL
,
Alset
AE
,
Say
EA
,
Caywood
E
,
Jabbour
P
,
Shields
JA
.
Retinoblastoma control with primary intra-arterial chemotherapy: outcomes before and during the intravitreal chemotherapy era
.
J Pediatr Ophthalmol Strabismus
.
2016
;
53
(
5
):
275
84
. .
10.
Munier
FL
,
Gaillard
MC
,
Balmer
A
,
Soliman
S
,
Podilsky
G
,
Moulin
AP
, et al.
Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications
.
Br J Ophthalmol
.
2012
;
96
(
8
):
1078
83
. .
11.
Singh
G
,
Daniels
AB
.
Disparities in retinoblastoma presentation, treatment, and outcomes in developed and less-developed countries
.
Semin Ophthalmol
.
2016
;
31
(
4
):
310
6
. .
12.
Shields
CL
,
Manjandavida
FP
,
Lally
SE
,
Pieretti
G
,
Arepalli
SA
,
Caywood
EH
, et al.
Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma
.
Ophthalmology
.
2014
;
121
(
7
):
1453
60
. .
13.
Manjandavida
FP
,
Stathopoulos
C
,
Zhang
J
,
Honavar
SG
,
Shields
CL
.
Intra-arterial chemotherapy in retinoblastoma: a paradigm change
.
Indian J Ophthalmol
.
2019
;
67
(
6
):
740
. .
14.
Shields
CL
,
Say
EA
,
Pointdujour-Lim
R
,
Cao
C
,
Jabbour
PM
,
Shields
JA
.
Rescue intra-arterial chemotherapy following retinoblastoma recurrence after initial intra-arterial chemotherapy
.
J Fr Ophtalmol
.
2015
;
38
(
6
):
542
9
. .
15.
Meadows
A
,
Chintagumpala
M
,
Dunkel
I
,
Friedman
D
,
Stoner
J
,
Villablanca
J
.
Children’s oncology group (COG) trials for retinoblastoma
.
En: Clin Ophthalmic Oncol
.
2007
:
491
5
.
16.
Shields
CL
,
Mashayekhi
A
,
Au
AK
,
Czyz
C
,
Leahey
A
,
Meadows
AT
, et al.
The International classification of retinoblastoma predicts chemoreduction success
.
Ophthalmology
.
2006
;
113
(
12
):
2276
80
. .
17.
Munier
FL
,
Beck-Popovic
M
,
Chantada
GL
,
Cobrinik
D
,
Kivelä
TT
,
Lohmann
D
, et al.
Conservative management of retinoblastoma: challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”
.
Prog Retin Eye Res
.
2019
;
73
:
100764
.
18.
RStudio Team
.
RStudio: Integrated Development Environment for R. RStudio, PBC
.
Boston, MA
;
2020
.
Available from: http://www.rstudio.com/
.
19.
Therneau
T
.
A Package for Survival Analysis in R. R package version 3.2-3
.
2020
. .
20.
Kassambara
A
,
Kosinski
M
,
Biecek
P
.
Survminer: Drawing Survival Curves using “ggplot2”. R package version 0.4.8.999
.
2020
. .
21.
EL CONGRESO DE LA REPUBLICA DE COLOMBIA. LEY NUMERO 100 DE [Internet]. Sec. II, 100 dic 23. 1993. p. 68. Disponible en. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/ley-100-de-1993.pdf
22.
González
M
,
Gaviria
ML
,
Giraldo
D
,
Alexandra
C
,
Robayo
JP
,
Fox
J
, et al.
Retinoblastoma in Colombia. XXXIV Pan-American Asociation of Ophthalmology
;
2019
; Cancún
.
23.
Naseripour
M
.
“Retinoblastoma survival disparity”: the expanding horizon in developing countries
.
Saudi J Ophthalmol
.
2012
;
26
(
2
):
157
61
.
24.
Lin
P
,
O’Brien
JM
.
Frontiers in the management of retinoblastoma
.
Am J Ophthalmol
.
2009
;
148
(
2
):
192
8
. .
25.
Fernandes
AG
,
Pollock
BD
,
Rabito
FA
.
Retinoblastoma in the United States: a 40-Year incidence and survival analysis
.
J Pediatr Ophthalmol Strabismus
.
2018
;
55
(
3
):
182
8
.
26.
MacCarthy
A
,
Birch
JM
,
Draper
GJ
,
Hungerford
JL
,
Kingston
JE
,
Kroll
ME
, et al.
Retinoblastoma: treatment and survival in Great Britain 1963 to 2002
.
Br J Ophthalmol
.
2009
;
93
(
1
):
38
9
. .
27.
Funes
S
,
Sampor
C
,
Villasante
F
,
Fandiño
A
,
Manzitti
J
,
Sgroi
M
, et al.
Feasibility and results of an intraarterial chemotherapy program for the conservative treatment of retinoblastoma in Argentina
.
Pediatr Blood Cancer
.
2018
;
65
(
8
):
e27086
. .
28.
Leal-Leal
CA
,
Asencio-López
L
,
Higuera-Calleja
J
,
Bernal-Moreno
M
,
Bosch-Canto
V
,
Chávez-Pacheco
J
, et al.
Globe salvage with intra-arterial topotecan-melphalan chemotherapy in children with a single eye
.
Rev Invest Clin
.
2016
;
68
(
3
):
137
42
.
29.
Habre
W
,
Disma
N
,
Virag
K
,
Becke
K
,
Hansen
TG
,
Jöhr
M
, et al.
Incidence of severe critical events in paediatric anaesthesia (APRICOT): a prospective multicentre observational study in 261 hospitals in Europe
.
Lancet Respir Med
.
2017
;
5
(
5
):
412
25
. .
30.
Suzuki
S
,
Yamane
T
,
Mohri
M
,
Kaneko
A
.
Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis
.
Ophthalmology
.
2011
;
118
(
10
):
2081
7
. .
31.
Abramson
DH
,
Marr
BP
,
Francis
JH
,
Dunkel
IJ
,
Fabius
AWM
,
Brodie
SE
, et al.
Simultaneous bilateral ophthalmic artery chemosurgery for bilateral retinoblastoma (Tandem Therapy)
.
PLoS One
.
2016 Jun 3
;
11
(
6
):
e0156806
. .
32.
Sweid
A
,
Hammoud
B
,
Texakalidis
P
,
Xu
V
,
Shivashankar
K
,
Baldassari
MP
, et al.
The use of alternative routes for the delivery of intra-arterial chemotherapy for retinoblastoma
.
Neurosurgery
.
2020 Oct 15
;
87
(
5
):
956
963
.
33.
Jager
RD
,
Aiello
LP
,
Patel
SC
,
Cunningham
ET
.
Risks of intravitreous injection: a comprehensive review
.
Retina
.
2004
;
24
(
5
):
676
98
. .
34.
Abramson
DH
,
Ji
X
,
Francis
JH
,
Catalanotti
F
,
Brodie
SE
,
Habib
L
.
Intravitreal chemotherapy in retinoblastoma: expanded use beyond intravitreal seeds
.
Br J Ophthalmol
.
2019
;
103
(
4
):
488
93
. .
35.
Yousef
YA
,
Soliman
SE
,
Astudillo
PP
,
Durairaj
P
,
Dimaras
H
,
Chan
HS
, et al.
Intra-arterial chemotherapy for retinoblastoma: a systematic review
.
JAMA Ophthalmol
.
2016
;
134
(
5
):
584
91
. .
36.
Ravindran
K
,
Dalvin
LA
,
Pulido
JS
,
Brinjikji
W
.
Intra-arterial chemotherapy for retinoblastoma: an updated systematic review and meta-analysis
.
J Neurointerv Surg
.
2019
;
11
(
12
):
1266
72
. .
37.
van Swieten
JC
,
Koudstaal
PJ
,
Visser
MC
,
Schouten
HJ
,
van Gijn
J
.
Interobserver agreement for the assessment of handicap in stroke patients
.
Stroke
.
1988
;
19
(
5
):
604
7
. .
38.
Akyüz
C
,
Kıratlı
H
,
Şen
H
,
Aydın
B
,
Tarlan
B
,
Varan
A
.
Intra-arterial chemotherapy for retinoblastoma: a single-center experience
.
Ophthalmologica
.
2015
;
234
(
4
):
227
32
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.